# Empagliflozin for No-reflow Phenomenon in PCI for STEMI

Study · id `cardio:ct-nct06342141` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06342141](<https://clinicaltrials.gov/study/NCT06342141>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06342141

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease; Acute care and long-term living  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 162 participants.

## Technical summary

Registry record NCT06342141. Randomized; triple masking; primary purpose prevention. Start 2024-08-22 (actual); primary completion 2026-03-15 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose prevention
- Phase: Phase 2
- Enrolled: 162 participants (planned count; ClinicalTrials.gov record NCT06342141, source copy `cardio:ctgov-nct06342141-2026-04-15`, retrieved 2026-10-26)
- Started: 2024-08-22 (actual) (ClinicalTrials.gov record NCT06342141, source copy `cardio:ctgov-nct06342141-2026-04-15`, retrieved 2026-10-26)
- Primary completion: 2026-03-15 (actual) (ClinicalTrials.gov record NCT06342141, source copy `cardio:ctgov-nct06342141-2026-04-15`, retrieved 2026-10-26)
- Completion: 2026-06-15 (anticipated) (ClinicalTrials.gov record NCT06342141, source copy `cardio:ctgov-nct06342141-2026-04-15`, retrieved 2026-10-26)
- Countries: Mexico (ClinicalTrials.gov record NCT06342141, source copy `cardio:ctgov-nct06342141-2026-04-15`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "ACTIVE\_NOT\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06342141-2026-04-15`, retrieved 2026-10-26)

## The registry's words

- Brief title: Empagliflozin for No-reflow Phenomenon in PCI for STEMI
- Acronym: EMPA-PCI
- Condition: STEMI
- Condition: No-Reflow Phenomenon
- Intervention (Drug): Empagliflozin 25 milgrams (Mg)
- Intervention (Drug): Empagliflozin 10 Mg
- Lead sponsor: Instituto Nacional de Cardiologia Ignacio Chavez
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Heart attack (myocardial infarction) (`cardio:myocardial-infarction`)
- Registry condition terms include this condition: ST-elevation heart attack (STEMI) (`cardio:stemi`)
- Registry lists this organization as the lead sponsor: Instituto Nacional de Cardiologia Ignacio Chavez (`cardio:org-instituto-nacional-de-cardiologia-ignacio-chavez`)

## Provenance

Content hash: 797710ac89692eee11feacf31db96e5d2a8113d01da92b8948bde3bb10945fc0
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
